An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences
Authors
Keywords
-
Journal
MILBANK QUARTERLY
Volume 89, Issue 3, Pages 450-502
Publisher
Wiley
Online
2011-09-21
DOI
10.1111/j.1468-0009.2011.00636.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?
- (2011) Bhaven N. Sampat et al. HEALTH AFFAIRS
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
- (2011) Aaron S. Kesselheim JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- “Pay for Delay” Settlements of Disputes over Pharmaceutical Patents
- (2011) Aaron S. Kesselheim et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Public-Sector Research in the Discovery of Drugs and Vaccines
- (2011) Ashley J. Stevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of orphan drug applications that fail to achieve marketing approval in the USA
- (2010) Harald E. Heemstra et al. DRUG DISCOVERY TODAY
- Safety-Related Regulatory Actions for Orphan Drugs in the US and EU
- (2010) Harald E. Heemstra et al. DRUG SAFETY
- State Generic Substitution Laws Can Lower Drug Outlays Under Medicaid
- (2010) William H. Shrank et al. HEALTH AFFAIRS
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
- (2010) R. Sridhara et al. JNCI-Journal of the National Cancer Institute
- Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation
- (2010) Aaron S. Kesselheim NEW ENGLAND JOURNAL OF MEDICINE
- Market Exclusivity for Biologics
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Pivotal studies of orphan drugs approved for neurological diseases
- (2009) Jun Mitsumoto et al. ANNALS OF NEUROLOGY
- Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration
- (2009) Barbara M Davit et al. ANNALS OF PHARMACOTHERAPY
- Orphan drug development is not taking off
- (2009) Roberta Joppi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Translation of rare disease research into orphan drug development: disease matters
- (2009) Harald E. Heemstra et al. DRUG DISCOVERY TODAY
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
- (2009) Olivier Wellman-Labadie et al. HEALTH POLICY
- R&D policy, agency costs and innovation in personalized medicine
- (2009) Wesley Yin JOURNAL OF HEALTH ECONOMICS
- Orphan products: an emerging trend in drug approvals
- (2009) Timothy Coté et al. NATURE REVIEWS DRUG DISCOVERY
- Balancing Innovation and Access: Patent Challenges Tip the Scales
- (2009) M. J. Higgins et al. SCIENCE
- The economic returns of pediatric clinical trials of antihypertensive drugs
- (2008) Carissa M. Baker-Smith et al. AMERICAN HEART JOURNAL
- Academic Patents and Access to Medicines in Developing Countries
- (2008) Bhaven N. Sampat AMERICAN JOURNAL OF PUBLIC HEALTH
- The economics of pediatric formulation development for off-patent drugs
- (2008) Christopher-Paul Milne et al. CLINICAL THERAPEUTICS
- Clinical and economic burden of antimicrobial resistance
- (2008) Lisa L Maragakis et al. Expert Review of Anti-Infective Therapy
- Pediatric Antihypertensive Trial Failures
- (2008) Daniel K. Benjamin et al. HYPERTENSION
- Market incentives and pharmaceutical innovation
- (2008) Wesley Yin JOURNAL OF HEALTH ECONOMICS
- Drug Development for Neglected Diseases — The Trouble with FDA Review Vouchers
- (2008) Aaron S. Kesselheim NEW ENGLAND JOURNAL OF MEDICINE
- Incentives for orphan drug research and development in the United States
- (2008) Enrique Seoane-Vazquez et al. Orphanet Journal of Rare Diseases
- Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity
- (2008) P. B. Smith et al. PEDIATRICS
- Improving Pediatric Dosing Through Pediatric Initiatives: What We Have Learned
- (2008) W. Rodriguez et al. PEDIATRICS
- Prioritizing Future Research on Off-Label Prescribing: Results of a Quantitative Evaluation
- (2008) Surrey M Walton et al. PHARMACOTHERAPY
- Is Bayh-Dole Good for Developing Countries? Lessons from the US Experience
- (2008) Anthony D So et al. PLOS BIOLOGY
- The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
- (2007) B. Spellberg et al. CLINICAL INFECTIOUS DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started